Overview

Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression

Status:
Unknown status

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

The investigators' experimental study found that gossypol was the natural inhibitor of apyrimidinic endonuclease 1 (APE1) and clinical study observed that high expression of APE1 was relative to the platinum-resistance in non-small cell lung cancer. Thus the purpose of this study is to find out whether gossypol can improve the sensitivity of cisplatin-based chemotherapy in the non-small cell lung cancer with apurinic apyrimidinic endonuclease 1 (APE1) high expression

Phase:

Phase 3

Details

Lead Sponsor:

Third Military Medical University

Treatments:

Cisplatin
Docetaxel
Gossypol
Gossypol acetic acid